Caris Life Sciences officer plans $238K stock sale

An officer of Caris Life Sciences has filed a Rule 144 notice to resell 7,500 common shares originally acquired in a private transaction.

Rhea-AI Filing Summary

Caris Life Sciences, Inc. (CAI) is the issuer of common stock that an officer, John Russel Denton, has notified for potential resale under Rule 144. The notice covers 7,500 shares of common stock with an aggregate market value of $238,626.00, against approximately 282,595,000 shares of common stock outstanding. The shares were originally acquired from the issuer or an affiliate on June 18, 2025 in a private, cash transaction and are to be sold through Morgan Stanley Smith Barney LLC on or after September 22, 2026 on the NASDAQ market.

Key Figures

Shares to be sold: 7,500 shares Aggregate market value: $238,626.00 Shares outstanding: 282,595,000 shares +2 more

5 metrics

Shares to be sold 7,500 shares Common stock covered by the Rule 144 notice

Aggregate market value $238,626.00 Market value of the 7,500 CAI shares to be sold

Shares outstanding 282,595,000 shares Approximate Caris Life Sciences common shares outstanding

Acquisition date June 18, 2025 Date the 7,500 shares were acquired in a private transaction

Intended sale date September 22, 2026 Date listed for proposed NASDAQ sales under Rule 144

Key Terms

Rule 144, Private Acquisition from Issuer/Affiliate, aggregate market value, Executive Financial Services

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Private Acquisition from Issuer/Affiliate financial

"Common | 06/18/2025 | Private Acquisition from Issuer/Affiliate | Issuer"

aggregate market value financial

"Common | ... | 7500 | 238626.00 | 282595000 | 09/22/2026"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Executive Financial Services financial

"Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing for CAI disclose about planned share sales?

It discloses a planned resale under Rule 144 of 7,500 shares of Caris Life Sciences, Inc. common stock by officer John Russel Denton, with an aggregate market value of $238,626.00, expected to be sold through Morgan Stanley Smith Barney LLC on or after September 22, 2026.

Who is selling Caris Life Sciences (CAI) shares and in what amount?

Officer John Russel Denton plans to sell 7,500 shares of Caris Life Sciences, Inc. common stock under Rule 144. The shares were acquired in a private cash transaction from the issuer or an affiliate on June 18, 2025.

What is the market value of the CAI shares covered by this Rule 144 notice?

The notice lists an aggregate market value of approximately $238,626.00 for the 7,500 shares of Caris Life Sciences, Inc. common stock proposed to be sold.

How many Caris Life Sciences (CAI) shares are outstanding in relation to this sale?

The notice states there are approximately 282,595,000 shares of Caris Life Sciences, Inc. common stock outstanding. This figure serves as context for the 7,500 shares proposed for resale under Rule 144.

When were the CAI shares to be sold under Rule 144 originally acquired?

The 7,500 shares of Caris Life Sciences, Inc. common stock were acquired on June 18, 2025 in a Private Acquisition from Issuer/Affiliate, paid for in cash.

On which market and through which broker may the CAI shares be sold?

The shares may be sold on NASDAQ through Morgan Stanley Smith Barney LLC Executive Financial Services, as listed in the securities information for this Rule 144 notice.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/22/2026 - 04:09 PM Accepted by SEC EDGAR 09/22/2026 - 04:08 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002071923
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CARIS LIFE SCIENCES, INC.
SEC File Number	001-42706
Address of Issuer	750 W JOHN CARPENTER FREEWAY SUITE 800 IRVING TEXAS 75039
Phone	(866) 771-8946
Name of Person for Whose Account the Securities are To Be Sold	JOHN RUSSEL DENTON
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	7500	238626.00	282595000	09/22/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/18/2025	Private Acquisition from Issuer/Affiliate	Issuer			7500	06/18/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/22/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	John Russel Denton
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)